ArticleJournal of cellular biochemistry2014
Osteocytes serve as a progenitor cell of osteosarcoma.
Article in Journal of cellular biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Nanoparticles Targeting the Tumor Microenvironment for the Treatment of Osteosarcoma: Recent Progress and Perspectives.International journal of nanomedicine · 2026Review
- Constructing a ferroptosis-related prognostic model for osteosarcoma based on scRNA-seq dataset and WGCNA analysis.International journal of clinical and experimental pathology · 2025Article
- Global research trends and hotspots in metabolomics of osteosarcoma: a decade-spanning bibliometric and visualized analysis.Frontiers in immunology · 2024Article
- Review
- The osteocyte as a signaling cell.Physiological reviews · 2022Review
- Osteocytes and Cancer.Current osteoporosis reports · 2021Review
- Molecular mechanisms underpinning sarcomas and implications for current and future therapy.Signal transduction and targeted therapy · 2021Review
- Toward zonally tailored scaffolds for osteochondral differentiation of synovial mesenchymal stem cells.Journal of biomedical materials research. Part B, Applied biomaterials · 2019Article
- The Osteocyte Transcriptome Is Extensively Dysregulated in Mouse Models of Osteogenesis Imperfecta.JBMR plus · 2019Article
- Epigenetic alterations in mesenchymal stem cells by osteosarcoma-derived extracellular vesicles.Epigenetics · 2019Article
- The Emerging Role of Osteocytes in Cancer in Bone.JBMR plus · 2019Review
- c-Fos induces chondrogenic tumor formation in immortalized human mesenchymal progenitor cells.Scientific reports · 2018Article
- A canine in vitro model for evaluation of marrow-derived mesenchymal stromal cell-based bone scaffolds.Journal of biomedical materials research. Part A · 2018Article
- Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.Current osteoporosis reports · 2017Review
- Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.Trends in molecular medicine · 2017Review
- Downregulation of calbindin 1, a calcium-binding protein, reduces the proliferation of osteosarcoma cells.Oncology letters · 2017Article
- Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells.International journal of molecular sciences · 2017Article
- Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model.Genes & cancer · 2017Article
- Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns.Veterinary and comparative oncology · 2016Article
- Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.Stem cells international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteosarcoma (OSA) is the most common primary bone tumor in humans. However, the cell of origin of OSA is not clearly defined although there is evidence that osteoblasts may serve as OSA progenitors. The role of osteocytes, terminally differentiated osteoblasts, as OSA progenitors has yet to be described. Analysis of patient cDNA from publicly available microarray data revealed that patients with OSA have increased expression of dentin matrix phosphoprotein 1 (DMP1), a marker of osteocytes. Analysis of multiple murine, human, and canine OSA cell lines revealed DMP1 expression. To test the tumorigenic potential of osteocytes, MLO-Y4, a SV-40 immortalized murine osteocyte cell line, was injected into subcutaneous and orthotopic (intratibial) sites of mice. Tumor growth occurred in both locations. Orthotopic MLO-Y4 tumors produced mixed osteoblastic/osteolytic radiographic lesions; a hallmark of OSA. Together, these data demonstrate for the first time that osteocytes can serve as OSA progenitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.